Michael Chi, Chief Commercial Officer of Hims & Hers Health, Inc. (NYSE:HIMS), reported a significant transaction involving ...

Andrew Dudum, the CEO of Hims & Hers Health Inc. (NYSE:HIMS), recently sold shares worth approximately $815,029, according to ...

Citigroup has recently reduced Hims & Hers Health Inc (HIMS) stock to Sell rating, as announced on January 10, 2025, according to Finviz. Earlier, on January 7, 2025, BTIG Research had initiated the ...

Discover why Hims & Hers Health is a top telehealth leader with impressive growth potential and a promising future for ...

In recent trading, Hims & Hers Health Inc (HIMS) stock price has shown some volatility, fluctuating 9.60% over the last five trades and -10.88% over the past 30 trades. This represents a notable shift ...

Hims & Hers Health ( HIMS 6.30%) is coming off a fantastic year in 2024 when its share price skyrocketed 172%. The telehealth ...

Financial writer highlights undervalued Hims & Hers Health with impressive growth potential and innovative product launches, ...

Hims & Hers Health, Inc. (HIMS) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the ...

In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Atricure (ATRC – Research Report) and Hims ...

Welcome to this week’s installment of “The Short Interest Report” – The Fly’s weekly recap of short interest trends among some of the most ...